Back to Directory

Concr

LondonGreater London
Founded 2018
Bayesian oncology models for treatment-response prediction and research

Concr is a London biotechnology software company using astrophysics-derived Bayesian AI to model individual cancer biology and predict treatment responses.

Its FarrSight platform combines genomic, molecular and clinical datasets in digital twins, supporting research into patient stratification and oncology drug development.

In 2026, the company completed its retrospective VISION breast-cancer study and published peer-reviewed analysis of pancreatic cancer response prediction. FarrSight remains research-use-only and is not an approved clinical diagnostic.

SoftwareBiotechAI & Machine LearningBioinformatics & Data AnalysisOncology

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Company News13 Oct 2026

Concr's FarrSight Predicts Disease Control in Independent Validation on PASS-01 Pancreatic Cancer Trial

The PASS-01 team at University Health Network scored FarrSight's blinded predictions independently across 115 evaluable patients, giving an AUC of 74% for predicting disease control. Patients who received the regimen the platform favoured had a 26% lower hazard of death (HR 0.74). Concr describes FarrSight as research use only.

Source: ConcrRead source

Company Notes

Member of